COVID-19, ACE -inhibitors and angiotensin receptor blockers: The need to differentiate between early infection and acute lung injury / COVID-19, y IECA -inhibidores y bloqueadores de los receptores de angiotensina: la necesidad de diferenciar entre una infección temprana y una lesión pulmonar aguda
Rev. colomb. cardiol
;
27(3): 129-131, May-June 2020. graf
Article
in English
| LILACS, COLNAL
| ID: biblio-1289201
ABSTRACT
SARS-CoV-2, along with SARS-CoV and MERS-CoV, forms part of the three highly pathogenic coronaviruses identified since the start of the millennium.1,2 While SARS-CoV was identified on 2003 and MERS-CoV on 2012, the initial reports of SARS-CoV-2 (the etiological agent of COVID-19) were first released at the end of December 2019.3,4 Now, after less than four months, the virus has distributed globally and has become the focus of extensive medical research, as the number of cases keeps rising.A significant part of the investigative effort has been directed to the search for an effective therapy or intervention that could stop the spread of the disease or be used to effectively treat infected patients. Likewise, potential predisposing factors to develop a more severe clinical presentation are progressively being identified. Some of the more relevant are older age and the presence of certain comorbidities, such as cerebrovascular and coronary heart disease, hypertension and diabetes.58 It is important to highlight that the last two are chronic conditions commonly treated with ACE-inhibitors and angiotensin II type-I receptor blockers.911 However, the evidence suggests that these medications can upregulate the expression of angiotensin converting enzyme 2 (ACE2), the cellular receptor for both SARS-CoV and SARS-CoV-2.1116 Thus, a group of researchers hypothesized that ACE2-increasing drugs could raise the risk of infection and prompt a more severe clinical course or a fatal outcome in diabetic and hypertensive patients.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Acute Lung Injury
/
Acetylcholine Release Inhibitors
/
SARS-CoV-2
/
COVID-19
/
Infections
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Rev. colomb. cardiol
Journal subject:
Cardiology
Year:
2020
Type:
Article
Affiliation country:
Mexico
Institution/Affiliation country:
Hospital San José de Querétaro/MX
/
Monterrey Institute of Technology and Higher Education/MX
Similar
MEDLINE
...
LILACS
LIS